Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report

This controlled, open-label trial studied 28-day mortality in hospitalized COVID-19 patients randomized to receive oral or intravenous dexamethasone for up to 10 days or usual care alone. The authors found a proportional reduction of approximately one-third in patients receiving invasive mechanical ventilation and a proportional reduction of approximately one-fifth in patients receiving oxygen without invasive mechanical ventilation in those patients who received dexamethasone.